Publication date: Jun 05, 2026
We developed a colorimetric dot-blot aptamer assay to address the urgent need for accessible, high-performance SARS-CoV-2 diagnostics in resource-limited settings. Our in-house 96-well dot-blot platform featuring optimized PVDF membrane fluidics and standardized clamping combines nucleocapsid protein (N)-specific monoclonal antibody capture with biotinylated DNA aptamer detection, achieving high sensitivity (0. 5 ng/mL limit of detection) and exceptional specificity (0/36 false positives) for the conserved nucleocapsid protein. The assay demonstrates 2-fold greater sensitivity than conventional ELISA (p
| Concepts | Keywords |
|---|---|
| Antibody | aptamer |
| Colorimetric | colorimetric dot-blot assay |
| Fluidics | nucleocapsid protein |
| Laboratory | point-of-care diagnostics |
| PVDF membrane | |
| resource-limited settings | |
| SARS-CoV-2 |
Original Article
(Visited 1 times, 1 visits today)